Rivia secures 3 million euros in seed financing

Marc Nemitz Marc Nemitz | 12.06.2024

Swiss startup Rivia secures €3 million to further expand its AI-driven data platform for clinical trials and strengthen its market position

Zurich, Switzerland, June 12, 2024 - Swiss startup Rivia has closed a €3 million seed funding round. This was led by Speedinvest, with further participation from Amino Collective and Nina Capital. The funds will be used to build new engineering and customer service teams and drive product development. The aim is to fully exploit the potential of integrated trial data and establish Rivia as the leading data platform for clinical trials in the biopharma industry.

AI platform for analyzing study data

Rivia addresses a key challenge in the biotech industry: only 13% of therapies that enter clinical trials reach the market. The increasing complexity of therapeutic development and rising competitive pressure make efficient data analytics and integration critical. Rivia's AI-driven data platform provides a real-time view of trial data, accelerating the path to market for new therapies.

Our technology goes beyond data integration and transforms how biotechs evaluate their therapies throughout the development cycle.

Erik Scalfaro, CEO and Co-Founder of Rivia

Rivia was founded by experts in the biopharma industry who understand the weaknesses of the current system. The platform enables biotech companies to effectively analyze their trial data to find faster and more efficient development pathways. By eliminating fragmented data and outdated visualization tools, Rivia is impacting the clinical trial lifecycle.

Rivia's platform is already being used by customers in Europe and the US, including Abcentra. Chris Farina, CEO of Abcentra, says: "Rivia is revolutionizing how biotech companies make decisions based on trial data. By quickly accessing and maintaining all studies as dynamic, evolving data sets, Rivia saves time and improves our understanding of patient responses."

Over the past four years, we at Nina Capital have evaluated over 450 startups providing software to biotechs and pharmaceutical companies. Rivia stands out for its unique approach to centralizing and visualizing multiple data sources in real time

Marta G. Zanchi, Founder and Managing Partner at Nina Capital

Speedinvest: A major venture capital investor in Europe

Speedinvest is one of the most active venture capital investors in Europe, known for its support of emerging technology companies. We regularly report on Speedinvest's investments, including most recently Trawa, which secured 10 million euros for green and cheap electricity,roclub with a 4 million euro seed financing and Necture, which received 7 million euros for the electrification of vehicle fleets. Through these investments, Speedinvest continuously demonstrates its commitment to supporting innovative and forward-looking companies.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

Take care, give care

Did this news inform or entertain you? Then we would be happy if you tell your network about it.

Share on Linkedin Share on Facebook Share on Xing

Related companies

Speedinvest
Speedinvest
Investor Wien
Speedinvest
Speedinvest is one of the leading early-stage investors with managed assets exceeding 1 billion EUR.
marta
marta
Startup 2020 Berlin
marta

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts